Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

PURPOSE: To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a selective MEK inhibitor, in patients with BRAF V600–mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: A total of 43 patients with BRAF V600–mutant mCRC were treated with dabrafenib (150 mg twice...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Corcoran, Ryan B., Atreya, Chloe E., Falchook, Gerald S., Kwak, Eunice L., Ryan, David P., Bendell, Johanna C., Hamid, Omid, Messersmith, Wells A., Daud, Adil, Kurzrock, Razelle, Pierobon, Mariaelena, Sun, Peng, Cunningham, Elizabeth, Little, Shonda, Orford, Keith, Motwani, Monica, Bai, Yuchen, Patel, Kiran, Venook, Alan P., Kopetz, Scott
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2015
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4669588/
https://ncbi.nlm.nih.gov/pubmed/26392102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.63.2471
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky